Unlock the MRFF - Professor John Fraser AO Joins Call for Action on Medical Research Funding
April, 2026
De Motu Cordis Founder and Chief Medical Officer, Professor John Fraser AO, is among more than 60 of Australia’s most eminent scientists and industry leaders calling on the federal government to unlock the Medical Research Future Fund (MRFF).
Professor Fraser is one of three Foundation signatories – alongside University of Queensland colleagues Professor Trent Munro and Emeritus Professor Paul Young – on an open letter addressed to Health Minister Mark Butler, Minister for Disability and the NDIS Senator Jenny McAllister, and Aged Care Minister Sam Rae.
The letter, which also carries the signatures of three Nobel Laureates – Peter C Doherty, Professor Brian Schmidt AC, and Professor Barry Marshall AC – urges the government to release the MRFF’s committed funds and support Australia’s future as a global innovation leader.
The $25 billion MRFF was established to deliver up to $1 billion annually for lifesaving research, yet significant capacity remains underutilised. The signatories argue that without action, Australia risks losing a generation of scientific capability.
The open letter highlights several pressing concerns facing the sector. Current success rates for early-career research grants sit below five per cent. Australia’s research and development investment stands at 1.7 per cent of GDP, placing the nation in the bottom third of all OECD countries. The result is that Australia’s most promising researchers are leaving the system – or the country altogether.
The signatories are calling for three key actions: unlock the full capacity of the MRFF and deploy it as originally intended; make scientific research a viable and sustainable career; and link discovery to translation, manufacturing, and commercialisation to ensure Australia captures the benefits of its own breakthroughs.
As Professor Fraser wrote in his call to action, medical research is one of the few sectors where Australia consistently outperforms its size, delivering breakthroughs that save lives globally and returning nearly four dollars for every dollar invested.
The open letter was covered in The Australian on 30 March 2026, under the headline reporting that top scientists are demanding action on research funding to prevent an Australian brain drain.
De Motu Cordis is proud to see its Founder standing alongside Australia’s leading scientific voices in advocating for a stronger, better-funded research ecosystem – one that retains talent, accelerates translation, and secures the nation’s position as a global innovator.

About DMC
“DMC is a clinical stage pharma company.”
DMC was founded in Brisbane, Australia by Professor John Fraser, an Intensivist and groundbreaking clinician, researcher, and company founder. John is also founder of the Critical Care Research Group and is a co-founder of BIVACOR Pty Ltd. John co-founded the COVID-19 Critical Care Consortium that facilitated collecting over 35 million data points from ICU units worldwide and aided in the development of treatment pathways.
Since inception, DMC has raised over US $21m in Seed rounds primarily in Australia. The majority of funding to date have been secured via the Queensland Business Development Fund, high net worth individuals and Australian family offices. A Series A financing round is planned for H2 2025, which will ideally be anchored by a US based VC.

Meet our new Chief Operating Officer, Ludo Bonnet
With more than two decades in pharmaceutical development, Ludovic Bonnet has built a career turning rigorous science into real-world outcomes – from leading Europe’s first generic pMDI approval via in vitro equivalence to advancing over 30 vaccine programmes from concept to validation.

Unlock the MRFF – Professor John Fraser AO Joins Call for Action on Medical Research Funding
DMC Founder Professor John Fraser AO is among more than 60 leading scientists and three Nobel Laureates calling on the Australian Government to unlock the Medical Research Future Fund.

Redefining What’s Possible in Emergency Drug Delivery
At the demanding intersection where innovation meets commercial reality, DMC’s Legal Counsel, Sonia Barber stands out as a leader who speaks fluently across law, business, science and global strategy.

